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Objective: Late-life depression (LLD) is associated with development of different types
of dementia. Identification of LLD patients, who will develop cognitive decline, i.e., the
early stage of dementia would help to implement interventions earlier. The purpose of
this study was to assess whether structural brain magnetic resonance imaging (MRI) in
LLD patients can predict mild cognitive impairment (MCI) or dementia 1 year prior to the
diagnosis.
Methods: LLD patients underwent brain MRI at baseline and repeated clinical
assessment after 1-year. Structural brain measurements were obtained using Freesurfer
software (v. 5.1) from the T1W brain MRI images. MRI-based Random Forest classifier
was used to discriminate between LLD who developed MCI or dementia after 1-year
follow-up and cognitively stable LLD. Additionally, a previously established Random
Forest model trained on 185 patients with Alzheimer’s disease (AD) vs. 225 cognitively
normal elderly from the Alzheimer’s disease Neuroimaging Initiative was tested on the
LLD data set (ADNI model).
Results: MCI and dementia diagnoses were predicted in LLD patients with
76%/68%/84% accuracy/sensitivity/specificity. Adding the baseline Mini-Mental State
Examination (MMSE) scores to the models improved accuracy/sensitivity/specificity
to 81%/75%/86%. The best model predicted MCI status alone using MRI and
baseline MMSE scores with accuracy/sensitivity/specificity of 89%/85%/90%. The
most important region for all the models was right ventral diencephalon, including
Abbreviations: CC, corpus callosum; CTH, cortical thickness; LLD, late-life depression; RF, random forest method; R-HC,
right hippocampus; R-VD, right ventral diencephalon; SV, subcortical volumetric measurement.
†Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design
and implementation of ADNI and/or provided data but did not participate in analysis or writing of this
report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/
how_to_apply/ADNI_Acknowledgement_List.pdf
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hypothalamus. Its volume correlated negatively with the number of depressive episodes.
ADNI model trained on AD vs. Controls using SV could predict MCI-DEM patients with
67% accuracy.
Conclusion: LDD patients developing MCI and dementia can be discriminated from
LLD patients remaining cognitively stable with good accuracy based on baseline
structural MRI alone. Baseline MMSE score improves prediction accuracy. Ventral
diencephalon, including the hypothalamus might play an important role in preservation
of cognitive functions in LLD.
Keywords: depression, MCI, Alzheimer’s disease, Freesurfer, neurodegeneration, hypothalamus, ventral
diencephalon, depressive episodes
INTRODUCTION
Depression is associated with accelerated brain aging (Simon
et al., 2006; McKinney and Sibille, 2013; Koutsouleris et al., 2014),
and is a risk factor for different types of dementia (Aziz and
Steffens, 2013; Diniz et al., 2013; Byers and Yaffe, 2014; Cooper
et al., 2015; Mourao et al., 2015).
Unfortunately, early identification of predementia states in
people with LLD is challenging as reduced cognitive scores
can be confounded by the depressive state. Thus depression is
an exclusion criterion for some definitions of mild cognitive
impairment (MCI; Steffens et al., 2006). It is challenging
to predict whether cognitive impairment identified during a
depressive episode in a LLD patient will improve after treatment
of depression or will progress to dementia. However, it is known
that among seniors with MCI identified during a depressive
episode only 17% experienced cognitive improvement after
2 years of follow-up (Steffens et al., 2009). Early identification of
those LLD patients with increased risk of progressive cognitive
decline could allow for more targeted clinical actions, for instance
choice of antidepressant (du Jardin et al., 2016; García-Fuster and
García-Sevilla, 2016) or other interventions, (Ngandu et al., 2015)
and possibly neuroprotective drugs in the future.
Biomarkers known from Alzheimer’s disease (AD) research
may be used to identify a neurodegenerative process and/or
increased risk of developing dementia in LLD patients in
particular during a depressive episode when neurocognitive
functions may not be reliably assessed. The biomarkers
include amyloid-beta positron emission tomography (PET) brain
imaging, magnetic resonance imaging (MRI) based cortical and
subcortical structural measurements, cerebrospinal fluid tau, and
amyloid-beta levels (American Psychiatric Association, 2013;
Dickerson and Wolk, 2013). However, it is still not known if these
biomarkers can be utilized to identify or predict future cognitive
impairment (MCI or dementia status) in LLD.
The aims of this study were: (1) To assess whether structural
T1 weighted (T1W) 3D brain MRI obtained during the
depressive episode in LLD patients can discriminate LLD who
were diagnosed with MCI or dementia after 1-year follow-up
from cognitively stable LLD using Random Forest classifier.
(2) To identify which regions are affected in LLD with
subsequent cognitive impairment. (3) To evaluate the feasibility
of using biomarkers derived from AD research, by implementing
a classifier trained on structural 3D brain MRI from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) sample.
MATERIALS AND METHODS
Cohorts
Two cohorts were used in this study:
(1) PRODE (Prognosis of depression in the elderly) – was used
as the main cohort (Borza et al., 2015). The PRODE study is a
prospective multicenter study including 169 patients≥60 years
referred to treatment for depression at nine centers of geriatric
psychiatry in Norway (Borza et al., 2015). Exclusion criteria
were life threatening diseases and severe aphasia (as it would
reduce the validity of the neuropsychological assessment).
Clinical and neuropsychological data were collected using
standardized clinical, psychiatric, and neuropsychological
assessment (see below). Of the 169 patients, 126 underwent
brain MRI examination at inclusion (Lebedeva et al., 2015)
T1W 3D brain MRI images were available for 112 patients
(Figure 1).
(2) ADNI – An established classification model based on RF
trained to discriminate between patients with AD (n = 185)
and healthy controls (HC, n = 225) using Freesurfer (v. 5.1)
measurements from T1W 3D brain MRI was also used on
the PRODE dataset. The training data was obtained from
the ADNI database1. The ADNI was launched in 2003 as
a public-private partnership, led by Principal Investigator
Michael W. Weiner, MD. The primary goal of ADNI has been
to test whether serial MRI, PET, other biological markers, and
clinical and neuropsychological assessment can be combined
to measure the progression of MCI and early AD. AD patients
met the NINCDS/ADRDA criteria for probable AD. The T1W
3D MRI-Freesurfer based model had AD vs. HC accuracy
of 90% for the testing dataset and predicted conversion in
additional sample of MCI (n= 165) to AD with accuracy 79%.
The most important regions for the discrimination were: left
and right hippocampi, left amygdala, left and right entorhinal
cortices, and left inferior temporal cortex (Lebedev et al., 2014).
We hypothesized that this model could be used to predict
MCI/AD conversion in the PRODE cohort.
1adni.loni.usc.edu
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FIGURE 1 | Flow chart describing patient selection and attrition from admission to 1-year follow-up assessment. AD, Alzheimer’s disease; UD,
Unspecified dementia; MCI, mild cognitive impairment; CS, cognitively stable control group; mild cognitive disorder – F 06.7 (ICD-10).
Clinical and Neuropsychological
Assessment
Psychiatric evaluation and neuropsychological assessment were
performed three times: at admission to the department of
geriatric psychiatry (baseline) and discharge, and after 1-
year. At each participating center trained clinicians performed
the psychiatric and neuropsychological assessments using a
harmonized procedure and the same protocol (Borza et al., 2015).
Clinical assessments included: demographic information,
history of depression or other psychiatric condition, family
history of psychiatric problems, current psychiatric problems,
and treatment(s). Patients were diagnosed based on the criteria
of the 10th Revision of the International Classification of
Diseases and Health Related Problems (ICD-10; World Health
Organization [WHO], 1993). Cognition was measured with the
Mini Mental Status Examination, MMSE (Folstein et al., 1975)
and Informant Questionnaire on Cognitive Decline in the Elderly
(IQCODE-16; Jorm and Jacomb, 1989). At the 1-year follow-up
assessment patients were also diagnosed using Winblad’s criteria
for MCI (Winblad et al., 2004).
Patient Selection
Patients without dementia diagnoses according to ICD-10 criteria
at inclusion and a T1W 3D/structural brain MRI were included
in this study (n = 95, Figure 1). Not all the patients could
be included in the final analyses for a variety of reasons, as
specified in Figure 1. Based on the 1-year follow-up diagnosis
the patients were divided into one mild cognitive impairment-
dementia (MCI-DEM) group including those diagnosed with
either MCI (n = 21; Winblad et al., 2004) or dementia (n = 8,
including: Alzheimer’s disease n= 5, unspecified dementia n= 3)
[World Health Organization (WHO)]. A matched cognitively
stable (CS) group was selected from the remaining 51 patient
based on age and gender (n= 40) and controlling for the balance
in number of CS and MCI at each center of inclusion (Figure 1).
Ethics Statement
The participating patients and caregivers were given oral and
written information, and they subsequently gave their written
consent to participate. The PRODE study was approved by
Regional Committee of Medical Research Ethics and Privacy and
Data Protection Officer at Oslo University Hospital (approval
number 2009/1774).
MRI
MRI Acquisition
All scans were optimized and harmonized across centers based
on American College of Radiology (ACR) phantom and a healthy
volunteer. This study is based on T1 3D brain MRI obtained
with sagittal volumetric magnetization-prepared rapid gradient
echo (3D MP-RAGE) images using the ADNI T1W volume
protocol (Jack et al., 2008) in six PRODE centers with 1.5T
and 3T MRI scanners (see Supplementary Table S1). Inter-site
reliability for the six centers was estimated using the intra-class
correlation coefficient (ICC) using two-way random effect model
with absolute agreement (McGraw and Wong, 1996). ICC was
estimated for the average CTH and total volume of subcortical
structures (TSV) obtained from the Freesurfer parcellation and
segmentation (see below). Reliability test was performed using
SPSS software v. 22. Assessment showed acceptable results (Fleiss,
1986). ICC (CTH) = 0.88 and ICC (TSV) = 0.98. It has
been shown that Freesurfer output measurements are consistent
between 1.5T and 3T MRI (Han et al., 2006; Pfefferbaum et al.,
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2012), thus the data across the field strengths was merged. CS
group was matched on number of participants having 1.5 and 3T
scans in addition to the other criteria.
Image Processing
Cortical thickness and SV were used as main outcomes. The
T1W 3D MRI brain images were processed using Freesurfer
(v. 5.1), where regional cortical thicknesses and volumetric
measures were estimated. The software is well documented
and available for download online2. The processing steps
included cortical reconstruction and segmentation of gray
matter volumetric structures. This was followed by parcellation
of the cerebral cortex into units based on gyral and sulcal
structure (Destrieux et al., 2010). One hundred forty eight
CTH measures (74 from each hemisphere) and 54 regional
volumes were generated. All output was visually inspected
for segmentation and parcellation quality before the analysis.
Volumes of left and right white matter hypointensities, optic
chiasm, right and left vessel, and left and right choroid plexus
were excluded from further analysis. List of measurements
included in the analysis is provided in Supplementary Table
S2. The accuracy of the CTH and hippocampal volumes
measurements derived by this technique has been validated
by histological and manual measurements (Rosas et al., 2002;
Sánchez-Benavides et al., 2010). All volumetric structures were
normalized by the subject’s intracranial volume using the residual
approach (Jack et al., 1989). Brain structures in the left and
right hemisphere may have different degree of atrophy, thus
CTH and SV of the left and right hemisphere were treated
separately (Dolcos et al., 2002). Workflow is represented in
Figure 2.
Statistical Analysis
R programming language (R Core Team, 2016), version 3.3.0,
was used to compare demographic and clinical data, and to
create random-forest algorithm (RF) classification models. For
group comparisons of demographic and clinical variables, the
chi-squared test was used for categorical variables, and t-test
or Mann–Whitney where appropriate for continuous variables.
RF classification models were established using R packages
“random forest” (Liaw and Wiener, 2002) and “caret” (Kuhn
et al., 2016), ROC-curve and area under the ROC-curve (AUC)
were estimated and plotted using “pROC” package (Robin et al.,
2011). Regions important for the classification were correlated
with clinical and demographic variables.
Random Forest Algorithm and
Performance Assessment
Random forest method allows performing supervised
classifications based on an ensemble of classification trees
(Breiman, 2001). RF selects a bootstrapped subset of all
observations – about 66% per tree and random subset of all
predictors/features (here: CTH, SV) at each node of the tree.
RF uses the majority vote of its trees terminal nodes to predict
the class label of a new observation. Each tree casts a unit
2http://surfer.nmr.mgh.harvard.edu/
vote for the class. Thus, high numbers of decision trees are
expected to increase reliability of the results. For each predictor
a Gini index is estimated at each node. Overall importance of
a predictor for the model is based on the summation of the
decreases in the Gini index at each node (Breiman, 2001). The
remaining 33% of the data, i.e., out-of-bag (OOB) data, is used
to measure the RF performance. The classification error of the
OOB observations is referred to as OOB error (Breiman, 1996).
Kappa is another measure of performance demonstrating how
close the RF classifications were to the actual classes, controlling
for the accuracy of a random classifier as measured by the
expected accuracy. Kappa is suggested to provide more reliable
information regarding the classifier performance than actual
accuracy in case of different class distribution in the dataset
(Fleiss, 1971).
RF Procedure
Random forest method algorithm was used to discriminate
between the MCI-DEM or MCI and CS groups at 1-year follow-
up based on the CTH and SV measures separately and combined.
In addition, demographic and clinical information was added to
the models to test if performance could be further improved.
Only the clinical information obtained at inclusion was used to
assess if MCI-DEM statuses 1-year later could be predicted based
on the earliest available clinical data and in the depressive state.
PRODE Cohort Models
PRODE models
Five thousand decision trees were used in the RF classification
models. RF models were trained to discriminate between MCI-
DEM (n = 29) or MCI alone (n = 21) and corresponding CS
patients. When discriminating between MCI vs. CS, the number
of CS was reduced to 30 (from 40) matched on age and gender
and scanner field strength, in order to keep balance in group
class distribution. AUC, sensitivity/specificity, overall accuracy,
and kappa, were used to assess performance of the models.
Confidence intervals (CI) were estimated using bootstrapping
(n = 100). The most relevant structures for prediction of MCI-
DEM or MCI were correlated with clinical variables related
to depression in order to detect regions involved in both
pathological processes.
ADNI cohort models
The previously established ADNI model (Lebedev et al., 2014)
was implemented in the PRODE dataset to evaluate its ability to
discriminate between MCI-DEM (n= 29) and CS group (n= 51).
However, we did not expect the ADNI model to outperform the
PRODE models because it was trained on a data derived from AD
patients versus HC, not LLD and not converting to MCI.
RESULTS
Demographics
Clinical and demographic variables in MCI-DEM and CS groups
are provided in Table 1. MCI-DEM group had significantly
lower MMSE scores at all three time points compared with
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FIGURE 2 | Diagram of the brain magnetic resonance imaging (MRI) data processing (1) T1W 3D MRI brain images were analyzed in Freesurfer
software. Resulting measurements where used as input for the random forest classifications. (2a) In the prognosis of depression in the elderly (PRODE)
models, PRODE cohort was used as training and testing datasets. (2b) The Alzheimer’s Disease Neuroimaging Initiative (ADNI) models were trained on the ADNI
data (Alzheimer’s patients vs. healthy elderly). PRODE cohort was used as testing dataset.
CS group. Other variables did not differ between the groups.
Similarly, the MCI group alone did not differ from the matched
CS patients in terms of age (p = 0.21) or gender (p = 0.92).
Notably, the standard deviation of the MMSE scores increased
in the MCI/dementia group between assessments “at discharge”
and “follow-up,” reflecting increased variance in their cognitive
statuses.
Prediction of MCI and Dementia in LLD
PRODE (MCI-DEM vs. CS Group) Models
The model using SV+CTH as input had the best performance
in discrimination between MCI-DEM and CS groups. The
model using only SV as input had the best performance in
discrimination between MCI (excluding eight dementia patients)
and CS groups. Details are provided in Table 2. The model
using only CTH as input for the MCI vs. CS discrimination had
67% accuracy and sensitivity < 50%. MMSE score at inclusion
improved the models performance. Adding age, gender, or
education to the model did not affect the results. When excluding
patients with MADRS< 7 and MMSE< 26 at discharge (n= 4),
accuracy changed slightly from 76 to 74% using SV as input.
Brain Measurements Used in Prediction
The most relevant measurements for the models were
right ventral diencephalon (R-VD, mean decrease in Gini
index = 8.26), middle anterior corpus callosum (mid-anterior
CC, mean decrease in Gini index= 2.06) and right hippocampus
(R-HC mean decrease in Gini index = 1.47). For all the PRODE
models (Table 2), the same structures (R-VD, mid-anterior
CC, and R-HC) were the most important. When excluding
participants from each center, the same structures remained the
most important.
Relationship between Ventral Diencephalon and
Clinical and Demographic Measures
Right ventral diencephalon, mid-anterior CC, and R-HC volumes
were correlated with the number of depressive episodes
(adjusting for age, gender, and MMSE). The number of depressive
episodes had significant inverse association with R-VD (p= 0.02)
and mid-anterior CC (p = 0.04) volumes. Next, total ventricular
volume was added as a covariate to assess if structural changes
co-occur with ventricle expansion as an indirect measure of a
degenerative nature of the observed structural changes. Adjusting
for total ventricular volume negated the effect of number of
depressive episodes on R-VD volume (p= 0.12) and mid-anterior
CC volume (p = 0.08). No association was found between the
number of depressive episodes and R-HC volume. MMSE score
was associated with R-HC volume (p= 0.03), but not with R-VD
volume (p= 0.16) or mid-anterior CC volume (p= 0.18).
ADNI (MCI-DEM vs. CS Group) Model
The ADNI model trained on SV demonstrated better
performance on separating MCI-DEM vs. CS in the PRODE
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TABLE 1 | Demographic and clinical characteristics of the MCI-DEM and cognitively stable (CS) groups.
PRODE data set MCI-DEM CS Test statistics p-value∗
N 29 40 – –
Age – mean (SD) 78.1 (7,3) 76,4 (5,8) t = −1.5 0.31
Sex – n women (%) 22 (75%) 29 (72%) χ2 = 0.03 0.85
Education (total years) – mean (SD) 8.9 (2.79) 10.1 (2.61) t = −1.8 0,07
Number of depressive episodes – (range) 2.5 (0–4) 1.5 (0–4) z = −1.06 0.28
Age at depression onset – median (range) 29.7 (15–85) 35.0 (16–88) z = −1.02 0.3
MADRS-1 – median (range) 26 (15–52) 27 (0–48) z = −0.66 0.5
MADRS-2 9 (0–31) 7 (0–30) z = −0.44 0.65
MADRS-3 8 (0–35) 4.5 (0–30) z = −0.43 0.66
MMSE-1 – mean (SD) 24.6 (3.0) 26.4 (1,8) t = −2.71 0.005
MMSE-2 25 (2.8) 27 (1.9) t = −5.42 0.009
MMSE-3 23.8 (5.6) 28 (1.7) t = −5.90 <0.001
MCI-DEM – LLD patients who received diagnosis of mild cognitive impairment or dementia at 1-year follow-up assessment. CS – LLD patients who remain cognitively
stable at 1-year follow-up assessment.
∗t-test, Mann–Whitney U test or chi-square test as appropriate.
MADRS, Montgomery–Asberg Depression Rating Scale; MMSE, Mini Mental State Examination.
MADRS/MMSE – 1 - at inclusion, 2- at discharge, 3- after 1 year follow-up period.
dataset (accuracy = 67.0%) than the ADNI model trained on
CTH+SV (accuracy= 57.5%; Table 2).
DISCUSSION
In this study, we have demonstrated that LLD patients who
were diagnosed with MCI or dementia 1 year later can
be discriminated from cognitively stable LLD patients using
structural brain measurements with 76% accuracy. The best
model predicted MCI status alone using SV and MMSE scores
with accuracy/sensitivity/specificity of 89%/85%/90%.
To our knowledge this study is the first to build classification
models based on structural MRI measures to predict
development of MCI or dementia in LLD patients, and to assess
performance of a model trained for AD-HC discrimination
(ADNI model) on a LLD dataset (PRODE cohort). We used all
brain parenchyma volumes derived from the Freesurfer analysis,
and showed that volumes of R-VD, mid-anterior CC, and R-HC
were the most important for discrimination between MCI-DEM
and CS group.
We have found only one study using a classification approach
and MRI data to predict MCI diagnosis, but in non-depressed
elderly and based on arterial spin labeling. This study reported
that perfusion in a region of interest in the posterior cingular
cortex could distinguish those developing MCI from a CS group
with an AUC of 66% (Xekardaki et al., 2015).
Brain Regions Important for Prediction
of MCI and Dementia Diagnosis
The most important regions for predicting a diagnosis of MCI
or dementia after 1-year follow-up were volumes of R-VD, mid-
anterior CC, and R-HC, respectively.
Right ventral diencephalon was demonstrated to be the
most relevant structure. The ventral diencephalon in Freesurfer
includes several structures: hypothalamus with mammillary
body, subthalamic, lateral geniculate, medial geniculate and red
nuclei, substantia nigra and surrounding white matter. Some
of these structures, i.e., substantia nigra and red nuclei, are
not locate to the diencephalon but mesencephalon according
to standard anatomical nomenclature. The hypothalamus is
known to be strongly involved in depression. As a part of
hypothalamic–pituitary–adrenal (HPA) axis, it is crucial for
emotional behavior and stress response. There are numerous
studies showing dysregulation of the HPA axis in depression,
but also in aging and neurodegeneration (Sapolsky et al., 1986;
Sapolsky, 2000; Varghese and Brown, 2001; Du and Pang,
2015). It has also been proposed that HPA-axis dysfunction
is central to the development of AD (Ishii and Iadecola,
2015). Indeed, hypothalamic dysfunction can explain the overlap
in symptoms between depression and AD (mood, appetite,
sleep, memory, autonomic). Consistent with our finding, several
previous imaging studies have shown structural and functional
abnormalities in the hypothalamus in MCI, preclinical AD, and
AD compared with control groups (Callen et al., 2001; Nestor
et al., 2003; Cross et al., 2013; Brueggen et al., 2015). For instance,
Hall et al. (2008) have demonstrated reduced basal forebrain
and hypothalamus volumes in preclinical AD, and interestingly
the combination of reduced forebrain and hippocampal volumes
was associated with more rapid cognitive decline. However, to
the best of our knowledge the current study is the first study
to assess the role of the entire ventral diencephalon in the
context of neurodegeneration. There are two previous studies
examining the ventral diencephalon (segmented in Freesurfer)
in relation to mood disorders. The first showed that bilateral
ventral diencephalon volume obtained from Freesurfer was
one of three top-ranked endophenotypes of major depressive
disorder in an analysis of a high-dimensional set of over 11,000
traits (Glahn et al., 2012). The other study demonstrated that
volume of the ventral diencephalon discriminated patients with
major depressive disorder from those with bipolar depression
as well as controls (Sacchet et al., 2015). Taken together, these
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TABLE 2 | Performance of the random forest classification models based on baseline structural magnetic resonance imaging (MRI) measurements with
and without Mini-Mental State Examination scores.
Model AUC (95% CI) Sens/spec(accuracy) kappa
PRODE Training set: MCI-DEM (n = 29) vs. CS group (n = 40)∗
SV 0.802 (70.4%–90.0%) 68/84 (74.6) 0.46
CTH+SV 0.758 (64.5%–87.0%) 55/86 (76.0) 0.47
CTH+SV+MMSE1 0.867 (77.5%–95.9%) 75/86 (81.3) 0.61
SV+MMSE1 0.892 (75.1%–96.9%) 75/81 (81.3) 0.60
PRODE Training set: MCI (n = 21) vs. CS group (n = 30)∗
SV 0.773 (64.3%–90.3%) 65/86 (76.4) 0.50
CTH+SV 0.678 (51.78%–83.8%) 52/80 (70.5) 0.44
CTH+SV+MMSE1 0.867 (75.1%–98.2%) 76/90 (86.2) 0.71
SV+MMSE1 0.905 (81.4%–99.6%) 85/90 (90.1) 0.79
ADNI Training set: ADNI AD vs. ADNI Controls
Testing set: PRODE MCI-DEM (n = 29) vs. PRODE CS group (n = 51)∗∗
SV 0.737 (62.6%–84.7%) 65.5/68.6 (67) 0.40
CTH+SV 0.623 (50.1%–74.4%) 48/62 (57.5) 0.10
PRODE model – trained to discriminate between LLD who developed MCI or dementia and cognitively stable LLD.
ADNI model – trained to discriminate between non-depressed patients with Alzheimer’s disease and cognitively normal non-depressed elderly.
CTH, cortical thickness; SV, subcortical volumes; MC, mean curvature; OOB, out-of-bag; AUC, area under the ROC-curve; MMSE1, Mini–Mental State Examination
scores at admission; Sens/Spec, Sensitivity/specificity; NA, not applicable.
∗ Accuracy estimated for OOB set.
∗∗Accuracy Estimated for the testing dataset.
findings suggest that neurodegeneration in ventral diencephalon
including the hypothalamus might be a link between depression
and cognitive impairment.
After R-VD, CC (mid-anterior CC) and hippocampal (R-
HC) volumes were the most relevant structures for predicting
MCI-DEM. HPA-axis dysregulation is associated with elevated
cortisol levels (O’Brien, 1996; Du and Pang, 2015) which is
hypothesized to cause reduced CC and hippocampal volumes
due to neurotoxic effects (Bao et al., 2008; Liu et al., 2016). The
importance of CC volume for predicting MCI-DEM suggests
presence of inter-hemispheric disconnection already in the early
stages of the neurodegenerative process. Previously, it has been
shown that anterior, middle and posterior portions of the CC
have less volume in AD compared to controls, but only the middle
part was smaller in amnestic MCI compared with controls (Qiu
et al., 2016). Moreover, decreased volume of mid-anterior portion
of CC has been linked to the memory loss in MCI and AD
(Qiu et al., 2016). The present findings support a connection
between R-VD, R-HC, and CC pathology in the development
of MCI and dementia in LLD, which may be linked to HPA-
axis dysregulation. A previous study examining only CC volume
reported that structural changes in CC predicted MCI-to-AD
conversion after 2.5 years on average (Lee et al., 2016), similar to
the current study where a whole brain approach was used and
conversion was to MCI/dementia. Hippocampal abnormalities
are one of the most replicable findings in both depression and AD
(Kempton et al., 2011; Sabuncu et al., 2011). Hippocampus has
large bidirectional connection with the mammillary bodies of the
hypothalamus which also might explain the concordant changes
in these two structures. The limbic-diencephalic pathways,
including the mammillothalamic tract and the mammillary
bodies per se are crucial for episodic memory (Vann and Nelson,
2015; Aggleton et al., 2016). Hypometabolism in the mammillary
bodies has been shown in both MCI and AD (Nestor et al., 2003).
Limbic-diencephalic pathway dysregulation has been shown in
the earliest stages of AD (Acosta-Cabronero and Nestor, 2014).
Indeed, limbic regions, which are crucial for emotion processing,
are also crucial for episodic memory. Thus, abnormal limbic-
diencephalic interaction may be a core feature of in MCI-DEM
development in LDD.
Of note, only brain structures from the right hemisphere were
important for the classifications. This supports the right hemi-
aging model, proposing that the right hemisphere shows greater
age-related decline than the left hemisphere (Dolcos et al., 2002).
However, this model is based on behavioral data rather than
neuroimaging and the evidence has been controversial (Daselaar
and Cabeza, 2005).
Interestingly, the number of depressive episodes had
significant inverse association with the R-VD and mid-anterior
CC volumes. Previously, it was reported that the number
of depressive episodes is associated with reduced volume of
the dentate gyrus in patients with major depressive disorder
(Treadway et al., 2015). It is not known whether reductions of
R-VD and mid-anterior CC are developmental phenomena,
which leads to increase of the number of depressive episodes
or degenerative consequences of a larger number of depressive
episodes. However, including total ventricular volume to the
regression model negated the effect of the number of depressive
episodes on the R-VD volume and reduced on mid-anterior
CC, providing indirect evidence for the degenerative nature
of R-VD and mid-anterior CC reduction. Future studies using
longitudinal imaging data could uncover the causality.
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SV+CTH+MMSE Models
MCI-DEM had significantly lower MMSE scores at all three
time points compared to the CS group. Regardless of whether
cognitive assessment in depressed patients is confounded by
depression per se, including MMSE scores at admission improved
the model’s prediction of MCI and dementia. Along with
a recent study of Heser et al. (2016), the present results
suggest that even during the depressive episode cognitive
impairment require clinical attention as a possible sign of
incipient dementia. Given the highly significant difference in
MMSE scores at all three time points between the MCI/DEM
and CS group, the probability that there was a true difference
in MMSE scores between MCI-DEM and CS groups at
all time points is very high, suggesting that MMSE in an
appropriate additional predictor of MCI/AD even in LLD
groups.
There was no correlation between MMSE scores R-VD and
mid-anterior CC volumes suggesting that MMSE scores did not
bias classification results. The absence of correlation between
MMSE and the two main predictors suggested that MMSE
improved classification models performance by explaining
additional factor variance.
Predicting MCI-DEM vs. MCI
The SV model trained on MCI vs. CS demonstrated better
performance than the model trained on the mixed sample
of MCI-DEM dementia vs. CS. The reasons might be a
more heterogeneous pattern of structural brain changes across
dementias in the MCI/DEM combined group and presence of
larger variability in the stages of pathological process. On the
other hand, the CTH+SV model performed better on the mixed
MCI+DEM group compared with MCI only. One explanation
might be that CTH get altered in the later stages and/or more
severe cases of cognitive impairment in LLD and that relevance
of the structural brain measurement as a biomarker therefore
depends on the stage of the disease.
Predicting MCI-DEM Conversion in LLD
Using the ADNI Model
MCI-DEM status was discriminated from the CS group with 67%
accuracy using the ADNI model. In other words, patients in the
MCI-DEM group were more likely to be classified as cases than
those in CS group based on their baseline brain MRI.
Interestingly, the ADNI model trained only on SV had much
higher accuracy compared with the one trained on CTH+SV.
Taking into account that the most relevant structures for MCI-
CS discrimination (PRODE models) were subcortical structures
and that the model combining SV with CTH had higher
accuracy in MCI-DEM than in MCI alone, the present results
may suggest that in LLD patients, who will develop MCI or
dementia, neurodegeneration appears to start in subcortical
structures and spread up to the neocortex in later stages. In
agreement with our findings it has been shown that atrophy in
basal forebrain and hypothalamus but not neocortex, precedes
clinical symptoms of AD by 4.5–5 years (Brueggen et al., 2015).
Several earlier studies have shown hypometabolism restricted
to hippocampus and parahippocampal gyrus in MCI, whereas
AD had additional temporal neocortical hypometabolism (De
Santi et al., 2001; Nestor et al., 2003). Taken together, the
current results suggest that classification models for prediction of
MCI/preclinical AD should focus on subcortical structures rather
than the neocortex.
Limitations
One of the limitations of the present study is that the time interval
between MRI assessment and MCI diagnosis was relatively
short, thus it is possible that some CS patients could be
diagnosed with MCI/dementia at a later time point. Excluding
LLD participants with the lowest MADRS and MMSE scores
at discharge (n = 4) did not alter the results notably (no
substantial drop in accuracy) which indicate that the possibility
that some patients could receive MCI diagnosis earlier did not
bias the results strongly. Another issue is that MMSE might
not be sensitive enough to detect MCI. In any case, there
are no cognitive screening instruments validated for use in a
depressed elderly population according to our knowledge. All
the models including only brain measurements as predictors
had very good specificity and sufficient sensitivity. One of the
reasons for this might be the relatively small sample size.
In future studies classification models should be trained on
larger samples after longer follow-up periods. Inclusion of
MRI scans obtained from scanners with different magnetic
field strengths might be considered a limitation; however, it
was shown that Freesurfer output measurements are consistent
between 1.5T and 3T MRI, which was confirmed in our
reliability analysis. We have shown that ICC is high across
the centers. We also balanced the number of participants
from each center and verified the results excluding each
center, in order to assess reliability of the results which were
consistent.
Possible Practical Implementation
Our results suggest that LLD with smaller volumes of the R-VD,
mid-anterior CC, and R-HC and lower MMSE scores at inclusion
have a higher probability of receiving a diagnosis of MCI or
dementia the following year. These measurements can provide
clinicians with novel evidence for an expected trajectory of
cognitive functioning in LLD and help to define a target group
for interventions against cognitive decline (Bredesen, 2014).
Future mechanistic studies should verify processes underlying
diencephalic neurodegeneration in LLD patients.
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